Mirzaten Q-Tab (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine. It also antagonizes 5‑HT2 and 5‑HT3 receptors, which boosts overall serotonin transmission while reducing certain serotonin‑related side effects. This dual action contributes to its antidepressant effect.

The appropriate dose of Mirzaten Q-Tab is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions precisely.

The safety of mirtazapine in pregnancy and lactation has not been definitively established, and the product carries an unknown pregnancy category. Clinicians must weigh potential benefits against possible risks and discuss these considerations with the patient before use.

To place an order, submit an enquiry on the Mirzaten Q-Tab product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often causes more sedation and weight gain but may be beneficial for patients with insomnia or poor appetite. Its distinct receptor profile can be advantageous when SSRIs are ineffective or poorly tolerated.

Store Mirzaten Q-Tab at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat, and direct light to maintain potency throughout the shelf life.

Mirzaten Q-Tab is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, split, or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, suicidal thoughts especially early in treatment, and serotonin syndrome when combined with other serotonergic drugs. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to mirtazapine or any tablet excipients should avoid it. It is also contraindicated in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those who have experienced severe reactions to similar antidepressants. A healthcare professional should evaluate suitability before prescribing.